CytomX Therapeutics (CTMX) Cash from Operations (2014 - 2026)
CytomX Therapeutics (CTMX) posted Cash from Operations of 25549000.0 for Q1 2026, down 9.92% on a QoQ basis from 23243000.0 in Q4 2025, and down 21.41% year-over-year from 32510588.8 in Q1 2025.
CytomX Therapeutics (CTMX) Cash from Operations (2014 - 2026) Analysis & Trends
CytomX Therapeutics' Cash from Operations history runs 13 years deep, the most recent figure standing at 25549000.0 for Q1 2026.
- Quarterly Cash from Operations fell 21.41% year-over-year to 25549000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 80093000.0 (up 1.4% YoY) and the FY2025 annual result came in at 75587000.0, up 12.34% from the prior year.
- Cash from Operations was 25549000.0 for Q1 2026 at CytomX Therapeutics, down from 23243000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 9349000.0 in Q1 2023 and bottomed at 41313000.0 in Q1 2022.
- A 5-year average of 20834705.88 and a median of 21043000.0 in 2025 frame the typical range for Cash from Operations.
- Peak annual rise in Cash from Operations reached 122.63% in 2023, while the deepest fall reached 1476.67% in 2023.
- CytomX Therapeutics' Cash from Operations stood at 1393000.0 in 2022, then sank by 1476.67% to 21963000.0 in 2023, then rose by 9.36% to 19908000.0 in 2024, then decreased by 16.75% to 23243000.0 in 2025, then slipped by 9.92% to 25549000.0 in 2026.
- Business Quant data shows CTMX's Cash from Operations at 25549000.0 in Q1 2026, 23243000.0 in Q4 2025, and 15548000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -19.59 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 201.34 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.53 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.43 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 1.08 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -354.17 Mn |
| 10 | CytomX Therapeutics | 590.32 Mn | 243.61 Mn | - | -25.55 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -25.55 Mn |
| Mar 31, 2026 | -25.55 Mn |
| Dec 31, 2025 | -23.24 Mn |
| Dec 31, 2025 | -23.24 Mn |
| Sep 30, 2025 | -15.55 Mn |
| Sep 30, 2025 | -15.55 Mn |
| Jun 30, 2025 | -15.75 Mn |
| Jun 30, 2025 | -15.75 Mn |
| Mar 31, 2025 | -21.04 Mn |
| Mar 31, 2025 | -21.04 Mn |
| Dec 31, 2024 | -19.91 Mn |
| Dec 31, 2024 | -19.91 Mn |
| Sep 30, 2024 | -20.73 Mn |
| Sep 30, 2024 | -20.73 Mn |
| Jun 30, 2024 | -19.55 Mn |
| Jun 30, 2024 | -19.55 Mn |
| Mar 31, 2024 | -26.05 Mn |
| Mar 31, 2024 | -26.05 Mn |
| Dec 31, 2023 | -21.96 Mn |
| Dec 31, 2023 | -21.96 Mn |